Suchergebnisse - "Oglesby, Alan"

Prospective Validation of the Lupus Impact Tracker: A Patient‐Completed Tool for Clinical Practice to Evaluate the Impact of Systemic Lupus Erythematosus von Jolly, Meenakshi, Kosinski, Mark, Garris, Cindy P., Oglesby, Alan K.

“… Objective To evaluate the reliability, validity, responsiveness, and utility of the Lupus Impact Tracker (LIT). Methods This was a prospective longitudinal …”
Volltext

Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States von Brogan, Anita J., Davis, Ashley E., Mellott, Claire E., Fraysse, Jeremy, Metzner, Aimee A., Oglesby, Alan K.

“… Objective Cabotegravir long-acting (CAB–LA) administered every 2 months was approved in the USA as pre-exposure prophylaxis (PrEP) for individuals at risk of …”
Volltext

The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S von Gordois, Adam, Scuffham, Paul, Shearer, Arran, Oglesby, Alan, Tobian, Janet Ash

“… The Health Care Costs of Diabetic Peripheral Neuropathy in the U.S. Adam Gordois , MSC 1 , Paul Scuffham , PHD 1 , Arran Shearer , MSC 1 , Alan Oglesby , MPH 2 …”
Volltext

Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting von Toy, Edmond L., Vekeman, Francis, Lewis, Michael C., Oglesby, Alan K., Duh, Mei Sheng

“… To estimate real-world healthcare costs, resource utilization, and treatment patterns among metastatic melanoma (MM) patients who received a therapy …”
Volltext

Economic burden associated with adverse events in patients with metastatic melanoma von Arondekar, Bhakti, Curkendall, Suellen, Monberg, Matthew, Mirakhur, Beloo, Oglesby, Alan K, Lenhart, Gregory M, Meyer, Nicole

“… There are currently many approved agents for the treatment of metastatic melanoma (MM), the most aggressive form of skin cancer. Treatments may include …”
Weitere Angaben

Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens von Priest, Julie, Germain, Guillaume, Laliberté, François, Duh, Mei Sheng, Mahendran, Malena, Fakih, Iman, Oglesby, Alan

“… Introduction Dolutegravir/lamivudine (DTG/3TC) is a 2-drug regimen for HIV-1 treatment with long-term efficacy and good tolerability comparable to 3- or 4-drug …”
Volltext

Real-World Effectiveness of Dolutegravir/Lamivudine in People With HIV-1 in Test-and-Treat Settings or With High Baseline Viral Loads: TANDEM Study Subgroup Analyses von Benson, Paul, Kuretski, Jennifer, Donovan, Cynthia, Harper, Gavin, Merrill, Deanna, Metzner, Aimee A., Mycock, Katie, Wallis, Hannah, Brogan, Andrew P., Patarroyo, Jimena, Oglesby, Alan

“… Introduction Dolutegravir/lamivudine (DTG/3TC) was first approved by the US Food and Drug Administration in 2019 for the treatment of antiretroviral therapy …”
Volltext

Benchmarking HIV Quality Measures Across US Payer Types von Priest, Julie L, Irwin, Debra E, Evans, Kristin A, Oglesby, Alan K, Brady, Brenna L

“… Despite advances in antiretroviral therapy (ART), human immunodeficiency virus (HIV) remains a significant issue in the United States. Early diagnosis, …”
Weitere Angaben

Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study von Schneider, Stefan, Blick, Gary, Burke, Christina, Ward, Douglas, Benson, Paul, Felizarta, Franco, Green, Dallas, Donovan, Cynthia, Harper, Gavin, Merrill, Deanna, Metzner, Aimee A., Mycock, Katie, Wallis, Hannah, Patarroyo, Jimena, Brogan, Andrew P., Oglesby, Alan

“… Introduction Dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) are fixed-dose, complete, single-tablet, two-drug regimens (2DRs) …”
Volltext

A Retrospective Administrative Claims Database Evaluation of the Utilization of Belimumab in US Managed Care Settings von Ke, Xuehua, Eisenberg Lawrence, Debra F., Oglesby, Alan, Patel, Jeetvan, Kan, Hong, Boggs, Robert

“… Belimumab is an approved therapy for the treatment of systemic lupus erythematosus (SLE). This study examined the real-world utilization patterns of belimumab …”
Volltext

Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study von Mills, Anthony M., Brunet, Laurence, Fusco, Jennifer S., Wohlfeiler, Michael B., Garris, Cindy P., Oglesby, Alan K., Mrus, Joseph M., Lackey, Philip C., Fusco, Gregory P.

“… Introduction Dolutegravir (DTG), Elvitegravir (EVG), Raltegravir (RAL) and Darunavir (DRV) are commonly prescribed core agents for antiretroviral therapy …”
Volltext

Real-World Experience with Dolutegravir-Based Two-Drug Regimens von Collins, Bonnie, Dominguez, Megan, Pike, James, Mrus, Joseph, Mycock, Katie, Roberts, Jenna, Waller, John, Dhir, Shelly, Garris, Cindy, Riedel, David J., Ramgopal, Moti, Ward, Douglas J., Oglesby, Alan

“… Background. Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, …”
Volltext

A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma von Kaye, James A., Oglesby, A., Hackshaw, Michelle D., Khan, Shahnaz, Colosia, Ann, Skolnik, Jeffrey M.

“… This systematic literature review describes adverse events (AEs) among patients with soft tissue sarcoma (STS) who received second-line or later anticancer …”
Volltext

The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy von Vinik, Etta J, Hayes, Risa P, Oglesby, Alan, Bastyr, Edward, Barlow, Patricia, Ford-Molvik, Stephanie L, Vinik, Aaron I

“… This study was designed to develop and validate a patient-reported outcomes measure, sensitive to the different features of diabetic neuropathy (DN)-small …”
Weitere Angaben

Direct and indirect costs among employees with diabetic retinopathy in the United States von Lee, Lauren J., Yu, Andrew P., Cahill, Kevin E., Oglesby, Alan K., Tang, Jackson, Qiu, Ying, Birnbaum, Howard G.

“… ABSTRACT Objective: To examine, from the employer perspective, the direct (healthcare) and indirect (workloss) costs of employees with diabetic retinopathy …”
Volltext

Optimization of BMD Measurements to Identify High Risk Groups for Treatment—A Test Analysis von Johansson, Helena, Oden, Anders, Johnell, Olof, Jonsson, Bengt, de Laet, Chris, Oglesby, Alan, McCloskey, Eugene V, Kayan, Karthik, Jalava, Tarja, Kanis, John A

“… The aim of this study was to optimize the use of BMD measurements in case finding strategies. The use of clinical risk factors with and without BMD was …”
Volltext

Predicted Costs and Outcomes From Reduced Vibration Detection in People With Diabetes in the U.S von Shearer, Arran, Scuffham, Paul, Gordois, Adam, Oglesby, Alan

“… Predicted Costs and Outcomes From Reduced Vibration Detection in People With Diabetes in the U.S. Arran Shearer , MSc 1 , Paul Scuffham , PHD 1 , Adam Gordois …”
Volltext

The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy von Matza, Louis S, Rousculp, Matthew D, Malley, Karen, Boye, Kristina S, Oglesby, Alan

“… Background This study characterized the degree of change in health-related quality of life (HRQL) associated with change in visual acuity among patients with …”
Volltext

The association between diabetes related medical costs and glycemic control: A retrospective analysis von Oglesby, Alan K, Secnik, Kristina, Barron, John, Al-Zakwani, Ibrahim, Lage, Maureen J

“… The objective of this research is to quantify the association between direct medical costs attributable to type 2 diabetes and level of glycemic control. A …”
Volltext

Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus von Minshall, Michael E., Oglesby, Alan K., Wintle, Matthew E., Valentine, William J., Roze, Stéphane, Palmer, Andrew J.

“… This analysis provides an early estimate of the cost-effectiveness of adjunctive exenatide in treating type 2 diabetes mellitus in the United States. Data from …”
Volltext